Bio-Thera Solutions, Ltd., 

BAT1706 (Bevacizumab Biosimilar) Phase I Trial Enrolls Its First Subjects in NZ

Date: 2016-03-08Click:

On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosimilar), which is currently carrying out its global development plan, has enrolled its first two healthy subjects in New Zealand. This is the first clinical study of a bevacizumab biosimilar to be conducted overseas by a Chinese company. At present, the clinical study is proceeding as planned, with the phase I final report expected to be completed in February 2017.

The CEO of Bio-Thera, Dr. Li Shengfeng, believes that BAT1706 is leading the way for Bio-Thera's many other outstanding products to begin their own international clinical testing, and in the next few years we will be launching global clinical trials for over a dozen other biosimilar drugs. This will lay the foundation for Bio-Thera to achieve its goal of becoming the first global biopharmaceutical company in Guangzhou to launch "Proudly Made In China" products.